利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.024 秒)

    BENZOAZOLYPIPERAZINE DERIVATIVES HAVING MGLUR1- AND MGLUR5-ANTAGONISTIC ACTIVITY
    3.
    发明公开
    BENZOAZOLYPIPERAZINE DERIVATIVES HAVING MGLUR1- AND MGLUR5-ANTAGONISTIC ACTIVITY 有权
    具有MGLUR1-和MGLUR5-拮抗活性的苯并氮杂哌嗪衍生物

    公开(公告)号：EP1583763A1

    公开(公告)日：2005-10-12

    申请号：EP03814351.7

    申请日：2003-12-22

    申请人： Euro-Celtique S.A.

    发明人： SUN, Qun ,  TAFESSE, Laykea ,  VICTORY, Sam

    IPC分类号： C07D417/12 ,  C07D413/12 ,  C07D403/12 ,  C07D401/12 ,  A61K31/495 ,  A61P29/00 ,  A61P13/00

    CPC分类号： C07D417/12 ,  A61K31/495 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12

    摘要： A compound of formula (I) wherein Ar1, A, R3, x, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a “Benzoazolylpiperazine Compound”), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson’s disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, retricted brain function, Huntington’s chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of Benzoazolylpiperazine Compound are disclosed.

    摘要翻译： 其中Ar 1，A，R 3，x和m如本文所公开且Ar 2为苯并噻唑基，苯并恶唑基或苯并咪唑基或其药学上可接受的盐（“苯并唑基哌嗪化合物”）的组合物， 苯并唑基哌嗪化合物，以及治疗或预防疼痛，UI，溃疡，IBD，IBS，成瘾性病症，帕金森病，帕金森病，焦虑症，癫痫症，中风，惊厥，瘙痒症状，精神病，认知障碍，记忆 公开了在动物中施用有效量的苯并唑基哌嗪化合物，包括向有需要的动物给药，包括给予有效量的苯并唑基哌嗪化合物，其中所述化合物包含有效量的苯并咪唑基哌嗪化合物或其药学可接受的盐。

    BENZOAZOLYLPIPERAZINE DERIVATIVES HAVING VR1-ANTAGONIST ACTIVITY
    5.
    发明授权
    BENZOAZOLYLPIPERAZINE DERIVATIVES HAVING VR1-ANTAGONIST ACTIVITY 有权
    具有VR1拮抗剂活性的苯并唑基哌嗪衍生物

    公开(公告)号：EP1583763B1

    公开(公告)日：2008-03-26

    申请号：EP03814351.7

    申请日：2003-12-22

    申请人： Euro-Celtique S.A.

    发明人： SUN, Qun ,  TAFESSE, Laykea ,  VICTORY, Sam

    IPC分类号： C07D417/12 ,  C07D413/12 ,  C07D403/12 ,  C07D401/12 ,  A61K31/495 ,  A61P29/00 ,  A61P13/00

    CPC分类号： C07D417/12 ,  A61K31/495 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12

    摘要： A compound of formula (I) wherein Ar1, A, R3, x, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a “Benzoazolylpiperazine Compound”), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson’s disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, retricted brain function, Huntington’s chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of Benzoazolylpiperazine Compound are disclosed.

    摘要翻译： 其中Ar 1，A，R 3，x和m如本文所公开且Ar 2为苯并噻唑基，苯并恶唑基或苯并咪唑基或其药学上可接受的盐（“苯并唑基哌嗪化合物”）的组合物， 苯并唑基哌嗪化合物，以及治疗或预防疼痛，UI，溃疡，IBD，IBS，成瘾性病症，帕金森病，帕金森病，焦虑症，癫痫症，中风，惊厥，瘙痒症状，精神病，认知障碍，记忆 公开了在动物中施用有效量的苯并唑基哌嗪化合物，包括向有需要的动物给药，包括给予有效量的苯并唑基哌嗪化合物，其中所述化合物包含有效量的苯并咪唑基哌嗪化合物或其药学可接受的盐。